FDA panel: NSF incidence falls with gadolinium restrictions

The incidence of nephrogenic systemic fibrosis (NSF) in the U.S. following administration of gadolinium-based contrast agents is falling as healthcare providers restrict the use of MRI contrast in at-risk patient populations, according to an advisory panel meeting convened on Tuesday to discuss U.S. Food and Drug Administration regulation of the products.

Click here to read the rest of the article.